Tue, Sep 30, 2014, 6:16 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

iloveallahgod 48 posts  |  Last Activity: Sep 29, 2014 8:32 AM Member since: Dec 31, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
    Background of Invention: Contact dermatitis is responsible for over 5.6 million doctor visits each year in the United States and accounts for 15-20% of all occupational diseases. Including lost workdays and loss of productivity, the estimated total annual costs associated with occupational skin diseases approach $1 billion annually in the United States (CDC National Institute of Occupational Health, Update July 1997) and up to $3 billion annually in Germany (Merk, Baron et al. 2006). Eighty percent of contact dermatitis instances are due to irritants while in the other 20% the compound induces an immunologic cascade and are classified as allergic

  • "It is our opinion that clinical trials of muscle therapies for patients with DMD, especially
    those testing therapies in younger DMD patients, often have inadequate cardiac
    monitoring and rarely have cardiac endpoints. In light of these findings, the NHLBI
    Contemporary Cardiac Issues in Duchenne Muscular Dystrophy working group convened July 10-
    11, 2014 and recommended the following protocol for cardiac surveillance in current and future clinical trials:
    All Phase II or III trials of muscle therapies have sufficient cardiac monitoring with cardiac MRI.
    Cardiac MRI with LGE should be considered standard of care in every phase 2 or 3 clinical trial, and in phase 1 clinical trials lasting more than 6 months and evaluating therapeutic endpoints. Any protocol
    excluding cardiac monitoring should have sound rationale and protocol review by appropriate cardiac expertise to review justification." The FDA immediately thanked PPMD and added the recommendations to its regulatory docket.
    Will cardiac MRIs be added as primary endpoints in the eteplirsen Phase III trial? Sarepta should certainly expect them as additional focal points in subsequent DMD therapy trials.

  • iloveallahgod iloveallahgod Sep 23, 2014 7:58 AM Flag

    TKMR up 8.5% pre-market after company news release of participation in Wellcome Trust funding of Ebola treatment. No Sarepta news release, yet. No pre-market activity, either.

  • From Reuters: "Several experimental Ebola drugs, including compounds from Mapp Biopharmaceutical, Sarepta and Tekmira, will be tested in West Africa for the first time in a bid to fast-track trials, the Wellcome Trust charity said on Tuesday."

  • US Patent no. 8,835,402. Published September 16, 2014.

    Treating myotonic dystrophy, types 1 and 2 (DM1 and DM2). These types of dystrophy are associated with a variety of serious pathologies including muscle abnormalities and weakness, and in the heart, conduction abnormalities.

    According to the Myotonic Dystrophy Foundation website, DM1 affects 1 in 8000 individuals; DM2 slightly less (so around 1 in 4000 individuals for DM! and DM2).

    "Although the most pronounced characteristic of myotonic dystrophy is skeletal and smooth muscle dysfunction (weakness, stiffness, and pain), the condition can be present with issues such as reduced cognitive function, vision impairment, gastrointestinal disturbances, endocrine deficiency, fertility issues, cardiovascular dysfunction, personality abnormalities, and respiratory insufficiency, in addition to muscle complaints.

    The range of systems affected and the severity of symptoms seen can vary greatly between patients, even in the same family. However, an affected person does not typically exhibit all, or even most, of the possible symptoms. Often the disorder is mild and only minor muscle weakness or cataracts are seen late in life. At the opposite end of the spectrum, life-threatening neuromuscular, cardiac, and pulmonary complications can occur in the most severe cases when children are born with the congenital form of the disorder. " (Myotonic Dystrophy Foundation).

  • Reply to


    by thigrlsrk Sep 13, 2014 11:23 AM
    iloveallahgod iloveallahgod Sep 13, 2014 9:52 PM Flag

    Agreed, Thig. Looks like the second part of the trial was added. The first part of the trial, ending next month (though it could be ahead of schedule) determined maximum dose. The second part of the trial will be multi-dose, replicating clinical use. This does suggest progress and continued funding by NIH. Good signs!

  • Announced this morning. HEB up 20+%.

  • Reply to

    too much going on

    by brad_210000 Sep 6, 2014 8:47 PM
    iloveallahgod iloveallahgod Sep 7, 2014 7:41 AM Flag

    I agree, Thig, though Sarepta's flu drug would be used primarily in the hospital setting for treating severe cases because it is administered intravenously - at least for now.

  • Reply to

    More inconvenient facts

    by winterlion7722 Sep 4, 2014 9:45 AM
    iloveallahgod iloveallahgod Sep 4, 2014 9:55 AM Flag

    There are other exceptions to patent infringement that your Prosensa quote fails to mention. An important one in this case is whether the inventions are, indeed, the same. If not, then no patent infringement. While Sarepta and Prosensa use similar technologies for their exon-skipping drugs, the drugs themselves are distinctly different. Sarepta will prevail in the US patent interference proceeding and in the European appeal.

  • iloveallahgod iloveallahgod Sep 3, 2014 2:47 PM Flag

    Thanks for replying to the Nature article and pointing out morpholinos as a therapy. Interestingly, one other commenter mentioned that Ebola cures may already be in our homes: "According to Dr. David S. Fedson, (retired professor of medicine at the University of Virginia), and Dr. Steven M. Opal (a professor of medicine at Brown University), Atorvastatin could possibly cure Ebola Disease." Lipitor (Atorvastatin) is one of the most prescribed drugs in America.

  • Reply to


    by thigrlsrk Aug 30, 2014 9:26 PM
    iloveallahgod iloveallahgod Aug 31, 2014 12:40 PM Flag

    Pasteur, your usual response to someone asking for a source of your statements is to say you are not going to do the DD for them. I will placate your hypocrisy this time. Sarepta issued a press release on February 9, 2012 titled: "Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses". As a result of the demonstrated safety of these two drugs, DSMB recommended going forward with multiple ascending dose studies for both therapeutics.

  • Reply to


    by thigrlsrk Aug 30, 2014 9:26 PM
    iloveallahgod iloveallahgod Aug 31, 2014 11:30 AM Flag

    Sarepta's Ebola drug demonstrated positive safety results in humans in its phase I clinical trial.

  • Reply to

    New Sarepta Patent Application - German

    by iloveallahgod Aug 29, 2014 6:43 AM
    iloveallahgod iloveallahgod Aug 29, 2014 7:43 PM Flag

    Go to Espacenet (European Patent Office) and type in Sarepta under worldwide data base. Scroll down to no. 19. There may be others. I haven't checked.

  • Reply to

    New Sarepta Patent Application - German

    by iloveallahgod Aug 29, 2014 6:43 AM
    iloveallahgod iloveallahgod Aug 29, 2014 7:57 AM Flag

    Eugen Uhlmann is the chief science officer and co-founder of AduiTide Pharmaceuticals, in Germany, which bills itself as : "a biopharmaceutical company, which discovers and develops novel nucleic acid-based therapeutics to treat a number of diseases, including cancer, infectious diseases, asthma and allergies, and for use as vaccine adjuvant." Looks like Sarepta has an, as yet, unannounced relationship with AduiTide. I haven't checked the relationships of the other inventors but I suspect they are also with AduiTide Pharmaceuticals.

  • iloveallahgod by iloveallahgod Aug 29, 2014 7:02 AM Flag

    From Reuters: "Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday." That's scary.

  • iloveallahgod by iloveallahgod Aug 29, 2014 6:53 AM Flag

    From the Associated Press: "The World Health Organization says the past week has seen the highest increase of Ebola cases since the outbreak began, more evidence that the crisis is worsening."

  • INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY. July 17, 2014. This appears to be a German patent invented by UHLMANN EUGEN [DE]; JURK MARION [DE]; LEHMANN THOMAS [DE] . I do not recognize these inventors. Background of the invention: Toll-like receptors (TLRs) are present on certain cells of the immune system and have been shown to be involved in the innate immune response. In vertebrates, this family consists of proteins called TLR1 to TLR10, which are known to recognize pathogen associated molecular patterns from bacteria, fungi, parasites, and viruses. TLRs are a key means by which mammals recognize and mount an immune response to foreign molecules and also provide a means by which the innate and adaptive immune responses are linked. TLRs have also been shown to play a role in the pathogenesis of many diseases, including autoimmunity, infectious disease, and inflammation and the regulation of TLR-mediated activation. By using appropriate agents this may provide a means for disease intervention.
    Interestingly, I did not find this among those patents filed in the US Patent Office.

  • Reply to

    Shorts Thesis???

    by redsolocupifilluup Aug 23, 2014 11:38 AM
    iloveallahgod iloveallahgod Aug 24, 2014 9:59 PM Flag

    When did the twins lose ambulation? Was it by week 1, week 2, or week 5? Week 24 was when the clinical trial results were first reported by Sarepta but the twins may have been lost well before then. Nearly 3 years later, no other children on eteplirsen have lost ambulation.

  • Reply to

    Cost of ETEP extrapolated to other treatments!

    by firedin2010 Aug 21, 2014 9:53 AM
    iloveallahgod iloveallahgod Aug 21, 2014 11:50 AM Flag

    I wouldn't be surprised to learn that Sarepta tested the assay system and its potential already by providing remaining tissue samples of earlier biopsies to Flagship, comparing its earlier dystrophin findings, and was pleased with the results.

  • Reply to

    mandatory srpt read

    by simp08801 Aug 20, 2014 7:29 PM
    iloveallahgod iloveallahgod Aug 21, 2014 8:43 AM Flag

    That's Tekmira's Marburg drug - article on their work published in Nature this week.

13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.